key: cord-0832280-onfi5taw
authors: Turgeon, Ricky D.; Zieroth, Shelley; Bewick, David; Chow, Chi-Ming; Clarke, Brian; Cowan, Simone; Fordyce, Christopher B.; Fournier, Anne; Gin, Kenneth; Gupta, Anil; Hardiman, Sean; Jackson, Simon; Lau, Benny; Leong-Poi, Howard; Mansour, Samer; Marelli, Ariane; Quraishi, Ata Rehman; Roifman, Idan; Ruel, Marc; Sapp, John; Singh, Gurmeet; Small, Gary; Virani, Sean; Wood, David A.; Krahn, Andrew
title: Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence
date: 2020-06-02
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2020.05.033
sha: 03f9b4693a42f4f07083158b558d2d890535d6cc
doc_id: 832280
cord_uid: onfi5taw

nan

Correspondence to: Dr. Ricky Turgeon, Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, British Columbia, V6T 1Z3, Canada. Phone: 1-587-936-4999, Email: ricky.turgeon@gmail.com Word count: 1187/1200

References: 5/5 The COVID-19 pandemic invoked the need for prompt guidance and rapid research to address emerging clinical questions. In response to early theoretical concerns regarding the use of renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) and angiotensin receptor-neprilysin inhibitors (ARNIs) during the COVID-19 pandemic, the Canadian Cardiovascular Society (CCS) and

Canadian Heart Failure Society (CHFS) issued guidance to continue these therapies among patients with heart failure and hypertension. 1 This advice was consistent with statements from other organizations, including the American Heart Association, American College of Cardiology, Heart Failure Society of America, and European Society of Cardiology. 2 The CCS COVID-19 Rapid

Response Team subsequently updated and expanded upon these recommendations (https://www.ccs.ca/images/Images_2020/CCS_CHFS_Update_COVID__CV_medications_Mar2 0.pdf).

These preliminary, consensus-based recommendations were developed by balancing the known benefits of RAS blockers on morbidity and mortality in patients with cardiovascular disease (and potential harm from withdrawing therapy) against the absence of clinical evidence for harm at that time. In this article, we provide an expanded discussion of the emerging evidence regarding RAS blocker use in the COVID-19 pandemic.

Several competing mechanisms have been postulated based on preclinical studies that suggest the potential for either benefit or harm from RAS blockers in COVID-19. 2, 3 The initial concerns that prompted the CCS/CHFS guidance stemmed from the hypothesis that these medications may upregulate ACE2, which is used as an entry portal into pneumocytes and other cells by SARS-CoV-2. Theoretically, RAS blockers could increase both vulnerability for COVID-19 infection and illness severity. Conversely, other mechanisms have been proposed by which RAS blockers may be beneficial, including reducing angiotensin II-mediated lung injury and cytokine release via ACE2 upregulation, and even decreasing viral entry by formation of complexes between angiotensin II type-1 receptors and membrane-bound ACE2. Based on these hypotheses, RAS blockers could "restore the balance" and improve outcomes in patients with COVID-19. All of these hypotheses are plagued by the absence of any study data definitively demonstrating that RAS blockers meaningfully impact ACE2 activity in humans.

At least 18 observational studies addressing RAS blockers in COVID-19 have been reported as of May 23, 2020. [2] [3] [4] [5] Most, but not all, analyses provide reassuring evidence in support of the CCS/CHFS guidance. Nine of these studies, including patients from around the globe, have employed strategies to mitigate the potential confounding and bias inherent to observational studies, including multivariable-adjusted case-control studies and cohort studies implementing propensity score matching or overlap-weighting (see Supplementary Table S1 for citations and further details). Among the general population, three studies consistently found no association between prior use of RAS blockers and the risk of testing positive for COVID-19, 3 and one study did not find an association between RAS blocker use and COVID-19 hospitalization. 4 Findings have been less consistent among studies evaluating the risk of complications in patients with confirmed COVID-19: RAS blockers were associated with lower or neutral risk of death or intensive care admission in all but one study, which found them to be associated with a higher risk of hospitalization and intensive care admission. 5 Although most of these studies provide reassuring results, the inconsistency in findings between studies and important methodological limitations present in all available studies decrease the certainty of evidence. The method for ascertaining medication exposure in most studies resulted in a high risk of misclassification bias, with exposure definitions ranging from outpatient pharmacy fills prior to the pandemic, prior documentation in the electronic medical record, and use recorded on admission or throughout hospitalization for COVID-19. This bias risks distorting or even obscuring any association, whether beneficial or harmful, between RAS blockers and COVID-19 outcomes. However, one study minimized this bias by defining exposure based on outpatient prescription fills with sufficient supply, compared to non-RAS antihypertensives, and found no association between RAS blocker use and COVID-19 hospitalization. 4 Further sources of bias include potential selection bias relating to both RAS blocker use and COVID-19 testing, particularly in centres where testing capacity was limited during the study period and directed at vulnerable patients. 5 Finally, studies that defined RAS blocker exposure based on use in hospital further suffer from immortal-time bias, as patients classified in the RAS blocker group, by definition, had to survive long enough to be prescribed a RAS blocker in hospital. It is notable that the studies that suggested a beneficial association between RAS blocker use and COVID-19 outcomes had the highest risk of this bias (including references 3 and 4 in Supplementary Table S2 ).

As of May 21, 2020, 20 RCTs evaluating RAS blockers in COVID-19 (total target of approximately 24,666 patients) have been registered on clinicaltrials.gov (Supplementary Table S2 ). Many of these trials are already underway and are expected to be completed in late 2020 to early 2021.

The trials registered to-date have key differences that may offer important insights on this clinical question.

First, 19 of these trials are evaluating whether RAS blockers modulate disease severity in patients with confirmed SARS-CoV-2 infection (mostly hospitalized in a non-critical care setting at baseline), with primary outcomes ranging from death, hospitalization, and composite measures of organ dysfunction and severity. Conversely, the CORONACION trial (NCT04330300) is the only trial enrolling patients without COVID-19 infection at baseline to evaluate whether continuing RAS blockers for hypertension versus switching to an alternate antihypertensive agent for up to 12 months affects downstream risk of COVID-19 infection and related morbidity and mortality. In this respect, CORONACION will be the only trial testing whether RAS blockers predispose patients to a higher risk of COVID-19 infection.

Second, the trials differ subtly in terms of the tested intervention. Some trials are evaluating de novo ACEI or ARB initiation versus placebo in patients without heart failure or other indications for RAS blockers, thus directly testing whether short-term use of RAS blockers is beneficial in the management of COVID-19. Other studies aim to compare discontinuation versus continuation of established RAS blocker therapy among patients already receiving these medications for a chronic indication. These will provide definitive evidence regarding the net effect of continuing these therapies in patients with an indication for RAS blocker use and established COVID-19 infection. Notably, none of these trials are evaluating ARNI use.

Third, trials are testing a range of agents and doses (e.g. ramipril 2.5 mg orally once daily, valsartan 160 mg orally twice daily, captopril administered by nebulizer) for durations of 5 to 30 days, which will allow for the exploration of class effects and dose-response relationships.

Finally, although randomization eliminates most biases present in the published observational studies, 6 trials employing blinding of participants and outcome assessors and 2 open-label RCTs focusing on all-cause death will provide particularly robust evidence regarding the potential efficacy and safety of RAS blockers in patients with SARS-CoV-2 infection.

RAS blockers are pillars of the cardiovascular pharmacological armamentarium based on substantial RCT evidence of cardiovascular benefit. Evidence addressing their use during the COVID-19 pandemic is rapidly evolving. As we await definitive RCT evidence in COVID-19, the CCS/CHFS guidance remains to continue RAS blockers irrespective of SARS-CoV-2 infection, as supported by the majority of available observational studies.

Zieroth has received consulting fees from Novartis and participates in Novartis sponsored clinical trials

Dr. Clarke has participated in consultation/speaking engagements for Novartis Pharmaceuticals, Servier Laboratories and Boehringer Ingelheim Pharmaceuticals

National Advisory Board

Dr. Singh is on the Edwards Lifesciences Advisory Board

Dr. Virani receives grants and honoraria from Novartis and Servier

COVID-19 and use of ACEi/ARB/ARNi medications for heart failure or hypertension

The Coronavirus Conundrum: ACE2 and Hypertension Edition

Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)